Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

UT Southwestern Medical Center

EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 3 Jun 2026
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 3 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 3 Jun 2026
Overcoming resistance to frontline immunotherapy in kidney cancer
0:57
Overcoming resistance to frontline immunotherapy in kidney cancer
Tian Zhang • 13 Mar 2026
BOOST-RCC: evolocumab and nivolumab in metastatic renal cell carcinoma
1:51
BOOST-RCC: evolocumab and nivolumab in metastatic renal cell carcinoma
Tian Zhang • 13 Mar 2026
Prostate cancer at ASCO GU 2026: PEACE-3, BRCAAway, and T-cell engagers
1:24
Prostate cancer at ASCO GU 2026: PEACE-3, BRCAAway, and T-cell engagers
Tian Zhang • 3 Mar 2026
Kidney cancer highlights at ASCO GU 2026: LITESPARK-011 & LITESPARK-022
1:47
Kidney cancer highlights at ASCO GU 2026: LITESPARK-011 & LITESPARK-022
Tian Zhang • 3 Mar 2026
Future refinements for the treatment of low-grade and high-grade UTUC
0:35
Future refinements for the treatment of low-grade and high-grade UTUC
Vitaly Margulis • 11 Jun 2025
The potential of VTP in low-grade upper tract urothelial carcinoma
0:29
The potential of VTP in low-grade upper tract urothelial carcinoma
Vitaly Margulis • 10 Jun 2025
ENLIGHTED: padeliporfin vascular targeted photodynamic therapy in UTUC
1:17
ENLIGHTED: padeliporfin vascular targeted photodynamic therapy in UTUC
Vitaly Margulis • 2 Jun 2025
RCC trials at ASCO 2025: CheckMate 214, ARC-20, LITESPARK-004 and TRAVERSE
3:22
RCC trials at ASCO 2025: CheckMate 214, ARC-20, LITESPARK-004 and TRAVERSE
Tian Zhang • 1 Jun 2025
STAR-EV: neoadjuvant enfortumab vedotin and SBRT in MIBC
1:34
STAR-EV: neoadjuvant enfortumab vedotin and SBRT in MIBC
Tian Zhang • 1 Jun 2025
Ipilimumab and nivolumab induction in PDIGREE: step 1 findings in mccRCC
4:13
Ipilimumab and nivolumab induction in PDIGREE: step 1 findings in mccRCC
Tian Zhang • 1 Jun 2025
BOOST-RCC: evolocumab and nivolumab in ICI-refractory RCC
1:18
BOOST-RCC: evolocumab and nivolumab in ICI-refractory RCC
Tian Zhang • 26 Feb 2025
COSMIC-313: final results of first-line triplet therapy in advanced RCC
1:06
COSMIC-313: final results of first-line triplet therapy in advanced RCC
Tian Zhang • 26 Feb 2025
KEYMAKER-U03: targeted therapy combinations for ccRCC in substudy 03B
1:23
KEYMAKER-U03: targeted therapy combinations for ccRCC in substudy 03B
Tian Zhang • 24 Feb 2025
The content of VJOncology is intended for healthcare professionals